HHS is weighing whether to redesign its 340B rebate model pilot program after two federal court rulings blocked its implementation and the agency formally agreed to abandon the initiative.
On Feb. 13, the Health Resources and Services Administration issued a request for information to gather input from stakeholders on a potential rebate-based model under the 340B Drug Pricing Program. Comments are open through March 19.
Aimee Kuhlman, vice president of advocacy and grassroots at the American Hospital Association, said the group “welcomes HRSA’s attempt to gather detailed information about the impact of a rebate model.”…
